Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
174
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.

Diabetes, obesity & metabolism·2026
Same author

Gastric-type Histology Independently Predicts Poor Survival in Surgically-treated Cervical Adenocarcinoma.

Anticancer research·2026
Same author

Effect of an Atelocollagen-Loaded Hyaluronic Acid-Based Porous Scaffold on Healing in a Rabbit Model of Chronic Rotator Cuff Tear.

Journal of shoulder and elbow surgery·2026
Same author

A 3D-Printed Scaffolded Hydrogel Microneedle Array Biosensor for Real-Time, Continuous Monitoring.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Advanced engineering of hydrogel platforms for cancer immunotherapy via distinct administration routes.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy.

ACS nano·2026

相关实验视频

Updated: Jun 30, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K

使用多剂强化学习进行公正的特征选择,用于预测不良血糖事件.

Seo-Hee Kim1, Dae-Yeon Kim2, Sung-Wan Chun2

  • 1Department of ICT Convergence, Soonchunhyang University, Asan, South Korea.

Computers in biology and medicine
|March 23, 2024
PubMed
概括

这项研究引入了一个注意力模型,用于预测2型糖尿病患者的不良血糖事件,提前30分钟. 该模型使用Time2Vec和一个公正的特征选择算法来提高葡萄糖预测的准确性.

关键词:
注意力机制注意力机制深度学习是一种深度学习.功能选择 功能选择多代理学习多代理学习强化学习是一种强化学习.

更多相关视频

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

709
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

相关实验视频

Last Updated: Jun 30, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K
Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

709
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

科学领域:

  • 生物医学工程 生物医学工程
  • 人工智能在医学中的应用
  • 糖尿病管理 糖尿病管理

背景情况:

  • 预测血糖事件对于管理2型糖尿病至关重要.
  • 现有的模型可能无法完全捕捉葡萄糖水平,胰岛素和饮食摄入量的时间动态.
  • 电子医疗记录 (EMR) 包含用于预测建模的宝贵功能.

研究的目的:

  • 开发一种注意力模型,以提前30分钟预测不良血糖事件 (低血糖和高血糖).
  • 使用Time2Vec.ec.将胰岛素的时间信息和饮食摄入量纳入其中.
  • 使用公正的算法优化EMR中的特征选择.

主要方法:

  • 开发了一种基于注意力的深度学习模型,用于葡萄糖预测.
  • 利用Time2Vec编码时间特征,如胰岛素和餐时间.
  • 实施了一个基于代理贡献的公正特征选择算法.
  • 评估了102名2型糖尿病患者的持续血糖监测数据模型.

主要成果:

  • 在预测血糖状况方面获得高F1分数:正常血糖89.0%,低血糖60.6%,高血糖89.8%.
  • 该模型展示了对时间数据的有效编码,以提高葡萄糖的预测.
  • 功能选择算法通过优化EMR功能来改善整体模型性能.

结论:

  • 提议的注意力模型与Time2Vec和高级特征选择显示了对实时预测2型糖尿病的血糖事件的显著前景.
  • 这种方法可以帮助积极管理和预防不良的血糖结果.
  • 需要在不同的临床环境中进一步验证.